Evidence map›Paper›PMID 41724695›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adults.

Hannah M Klinger, Mabel Seto, Vaibhav A Janve, Jane A Brown, Michelle Clifton, Colin Birkenbihl, Gillian T Coughlan, Diana L Townsend, Michael Properzi, Jane Zyski and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Hannah M KlingerDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Mabel SetoDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Vaibhav A JanveVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jane A BrownDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Michelle CliftonVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Colin BirkenbihlDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Gillian T CoughlanDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Diana L TownsendDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Michael ProperziDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Jane ZyskiVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ting-Chen WangVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Rebecca E AmariglioCenter for Alzheimer's Research and Treatment, Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, Massachusetts, USA.
Kathryn V PappCenter for Alzheimer's Research and Treatment, Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, Massachusetts, USA.
Dorene M RentzCenter for Alzheimer's Research and Treatment, Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, Massachusetts, USA.
Hyun-Sik YangCenter for Alzheimer's Research and Treatment, Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, Massachusetts, USA.
Jasmeer ChhatwalDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Michael C DonohueAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Rema RamanAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Robert A RissmanAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Paul AisenAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Keith A JohnsonDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Reisa A SperlingDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Logan DumitrescuVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Timothy HohmanVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Rachel F BuckleyDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Funding

Accelerating Medicines PartnershipAlbert Einstein College of MedicineAlzheimer's AssociationAvidCogstateEli Lilly and CompanyFoundation for Neurologic DiseasesGerald and Henrietta Rauenhorst (GHR) FoundationNational Institutes of Health-National Institute on Aging DP2AG082342National Institutes of Health-National Institute on Aging R01AG063689National Institutes of Health-National Institute on Aging R01AG079142National Institutes of Health-National Institute on Aging U19AG010483National Institutes of Health-National Institute on Aging U24AG057437US Against Alzheimer's disease
6 · The paper itself

Abstract

introductionEarly biological pathways explaining the risk for Alzheimer's disease (AD)-related cognitive decline remain poorly understood.

methodsUsing linear mixed-effects models, we investigated whether whole blood gene expression (RNA sequencing) moderates the relationship between AD biomarkers measured by amyloid beta (Aβ) and tau-PET (positron emission tomography) imaging and longitudinal cognition in 770 cognitively unimpaired older adults (Age

resultsWe identified protective and AD risk-related gene expression signatures on the autosome and X chromosome. Six genes (n DISCUSSION: These findings underscore the importance of peripheral transcriptomic markers in identifying sex-differentiated pathways related to risk of and protection from cognitive decline in preclinical AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionGene ExpressionAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersFemaleHumansLongitudinal StudiesMalePositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkerstau Proteinsamyloidlongitudinal cognitionPACCPETRNAseqsex differencestauwhole blood gene expression

Identifiers

PMID41724695
PMCPMC12928093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.